[go: up one dir, main page]

AR081187A1 - Formulaciones inyectables parasiticidas de levamisol y lactonas macrociclicas. metodo de preparacion. metodo de tratamiento. - Google Patents

Formulaciones inyectables parasiticidas de levamisol y lactonas macrociclicas. metodo de preparacion. metodo de tratamiento.

Info

Publication number
AR081187A1
AR081187A1 ARP110101654A ARP110101654A AR081187A1 AR 081187 A1 AR081187 A1 AR 081187A1 AR P110101654 A ARP110101654 A AR P110101654A AR P110101654 A ARP110101654 A AR P110101654A AR 081187 A1 AR081187 A1 AR 081187A1
Authority
AR
Argentina
Prior art keywords
formulation
injection
levamisole
macrocyclic
lactone
Prior art date
Application number
ARP110101654A
Other languages
English (en)
Inventor
Jitendra Goswami
Robert Holmes
Majid Razzak
Atul Awasthi
Alan Johnson
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44342950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of AR081187A1 publication Critical patent/AR081187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones que contienen levamisol / lactona macrocíclica inyectables que son efectivas contra plagas animales incluyendo endoparásitos. Las formulaciones se pueden utilizar para combatir parásitos en aves y mamíferos. Método mejorado para erradicar, controlar y prevenir la infestación por parásitos de aves y mamíferos. Reivindicación 1: Una formulación farmacéutica o veterinariamente aceptable adaptada para ser inyectada a un animal, caracterizada porque dicha formulación comprende; a) una cantidad efectiva de un levamisol; b) una cantidad efectiva de por lo menos una lactona macrocíclica; c) un sistema farmacéuticamente aceptable de solventes y tensioactivos donde el sistema provee una estabilidad aceptable ante el almacenamiento tanto para el levamisol como la lactona macrocíclica y donde el sistema provee una viscosidad que es apropiada para la inyección; y donde el sistema comprende por lo menos un tensioactivo. Reivindicación 3: La formulación de la reivindicación 1, caracterizada porque la lactona macrocíclica es ya sea ivermectina o eprinomectina y está presente en una cantidad suficiente para administrar una dosis de por lo menos 150 microgramos/kg de peso corporal del animal. Reivindicación 4: La formulación de cualquiera de las reivindicaciones 1 o 3 caracterizada porque además comprende un antioxidante, un conservante, y agua apta para inyección donde el agua apta para inyección se provee en una cantidad suficiente para llevar la formulación a un volumen apropiado para inyectarla.
ARP110101654A 2010-05-12 2011-05-12 Formulaciones inyectables parasiticidas de levamisol y lactonas macrociclicas. metodo de preparacion. metodo de tratamiento. AR081187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33388210P 2010-05-12 2010-05-12

Publications (1)

Publication Number Publication Date
AR081187A1 true AR081187A1 (es) 2012-07-04

Family

ID=44342950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101654A AR081187A1 (es) 2010-05-12 2011-05-12 Formulaciones inyectables parasiticidas de levamisol y lactonas macrociclicas. metodo de preparacion. metodo de tratamiento.

Country Status (13)

Country Link
US (1) US20110281920A1 (es)
EP (1) EP2568980B1 (es)
AR (1) AR081187A1 (es)
AU (1) AU2011252987B2 (es)
DK (1) DK2568980T3 (es)
ES (1) ES2554245T3 (es)
HR (1) HRP20160103T1 (es)
HU (1) HUE028600T2 (es)
NZ (1) NZ603699A (es)
PL (1) PL2568980T3 (es)
PT (1) PT2568980E (es)
SI (1) SI2568980T1 (es)
WO (1) WO2011143479A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010101389C4 (en) * 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
CA2839491A1 (en) * 2011-06-23 2012-12-27 Bayer New Zealand Limited Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation
NZ594610A (en) 2011-08-16 2013-03-28 Virbac New Zealand Ltd Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
US20140045885A1 (en) * 2012-08-10 2014-02-13 Siobhan P. Ellison Decoquinate, 4-hydroxyquinolones and napthoquinones combined with levamisole, Imidazothiazole, for the prevention and treatment of sarcocystosis and equine protozoal myeloencephalitis caused by Sarcocystis and Neospora and other apicomplexan protozoans.
RU2527329C2 (ru) * 2012-10-25 2014-08-27 Государственное научное учреждение Курский научно-исследовательский институт агропромышленного производства Россельхозакадемии Способ получения комплексного иммунометаболического препарата с антиинфекционной активностью
WO2014098623A1 (en) * 2012-12-20 2014-06-26 Alleva Animal Health Limited Injectable eprinomectin formulation and anthelmintic use thereof
EP2983712B1 (en) 2013-04-12 2020-11-25 Zoetis Services LLC Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent
BR102013031277B1 (pt) 2013-12-05 2018-10-02 Ouro Fino Participacoes E Empreendimentos S A processo para preparar uma suspensão anti-helmíntica e suspensão anti-helmíntica injetável
AU2016200283B2 (en) * 2015-02-21 2016-10-13 Al Hanbali, Othman Abdul Rahim DR LEVIA: A New Injectable Parasiticidal Veterinary Formulation of Levamisole HCI and Ivermectin Solution
WO2018038623A1 (en) * 2016-08-23 2018-03-01 Donaghys Limited Improvements in parasite treatments

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4096271A (en) * 1977-08-03 1978-06-20 American Cyanamid Company Slow release injectable formulations of tetramisole and derivatives in benzyl benzoate
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4389397A (en) * 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
EP0237482A1 (de) 1986-03-06 1987-09-16 Ciba-Geigy Ag C(29)-Carbonyloxi-milbemycin-Derivate zur Bekämpfung von tier- und pflanzenparasitären Schädlingen
ES2019932B3 (es) 1986-03-25 1991-07-16 Sankyo Co Compuestos macrolidos.
ES2039258T3 (es) 1986-07-02 1993-09-16 Ciba-Geigy Ag Pesticidas.
US4855317A (en) 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
EP0319142B1 (en) 1987-11-03 1994-04-06 Beecham Group Plc Intermediates for the preparation of anthelmintic macrolide antibiotics
NZ232422A (en) 1989-02-16 1992-11-25 Merck & Co Inc 13-ketal milbemycin derivatives and parasiticides
US5602107A (en) 1993-05-10 1997-02-11 Merck & Co., Inc. Pour-on formulations consisting of gylcols, glycerides and avermectin compounds
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
AR035550A1 (es) * 1999-06-04 2004-06-16 Nufarm Ltd Composiciones estables biocidas
CR6574A (es) 2001-02-27 2004-10-28 Syngenta Participations Ag Sales de avermectinas substituidas en la posicion 4 con propiedades plaguicidas
EG23124A (en) 2001-02-27 2004-04-28 Syngenta Participations Ag Avermectins substituted in the 4-position having pesticidal properties
AR036486A1 (es) 2001-08-28 2004-09-15 Syngenta Participations Ag Derivados 4"-desoxi-4"-(s)-amino avermectina, composicion plaguicida, procedimiento para la preparacion de esa composicion, metodo para controlar plagas, y uso de estos derivados para preparar una composicion
AR037938A1 (es) 2001-12-21 2004-12-22 Syngenta Participations Ag Derivados de avermectina b1 que tienen un substituyente de aminosulfoniloxilo en la posicion 4''
NZ520295A (en) 2002-07-19 2005-04-29 Ashmont Holdings Ltd Anthelmintic formulations comprising levamisole and either an avermectin or milbemycin
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
GB0302308D0 (en) 2003-01-31 2003-03-05 Syngenta Participations Ag Avermectin and avermectin monosaccharide derivatives substituted in the 4"- or 4'-position having pesticidal properties
GB0302310D0 (en) 2003-01-31 2003-03-05 Syngenta Participations Ag Avermectin- and avermectin monosaccharide derivatives substituted in the 4"- or 4' - positionhaving pesticidal properties
AU2003900505A0 (en) * 2003-02-05 2003-02-20 Jurox Pty Ltd Anthelmintic composition
GB0313937D0 (en) 2003-06-16 2003-07-23 Syngenta Participations Ag Avermectin B1 monosaccharide derivatives having an aminosulfonyloxy substituentin the 4'-position
GB0320176D0 (en) 2003-08-28 2003-10-01 Syngenta Participations Ag Avermectins and avermectin monosaccharides substitued in the 4'-and 4"-positionhaving pesticidal properties
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
ATE406348T1 (de) * 2004-09-23 2008-09-15 Schering Plough Ltd Bekämpfung von parasiten in tieren durch verwendung neuer trifluormethansulfonanilidoximetherderivate
BRPI0506279B1 (pt) 2005-12-16 2018-01-09 Npa - Núcleo De Pesquisas Aplicadas Ltda Composição sinergística de antihelmínticos e endectocidas
US8399442B2 (en) * 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2010021555A1 (en) 2008-08-18 2010-02-25 Schering-Plough Animal Health Limited Anthelmintic compositions
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same

Also Published As

Publication number Publication date
AU2011252987A1 (en) 2012-12-13
PT2568980E (pt) 2016-03-15
ES2554245T3 (es) 2015-12-17
PL2568980T3 (pl) 2016-05-31
US20110281920A1 (en) 2011-11-17
NZ603699A (en) 2013-08-30
WO2011143479A1 (en) 2011-11-17
EP2568980A1 (en) 2013-03-20
SI2568980T1 (sl) 2016-02-29
EP2568980B1 (en) 2015-11-11
DK2568980T3 (en) 2015-11-30
HRP20160103T1 (hr) 2016-02-26
HUE028600T2 (en) 2016-12-28
AU2011252987B2 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
AR081187A1 (es) Formulaciones inyectables parasiticidas de levamisol y lactonas macrociclicas. metodo de preparacion. metodo de tratamiento.
ES2748631T3 (es) Combinaciones parasiticidas de isoxazolina espirocíclica
AR056808A1 (es) Formulacion de aceite en agua de avermectinas
CO2017007003A2 (es) Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares
CL2008003762A1 (es) Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes.
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
CL2015001981A1 (es) (divisional solicitud 1567-2013)combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
CL2017002164A1 (es) Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
AR090606A1 (es) Composicion pesticida
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
AU2022252717A1 (en) Stable veterinary anthelmintic formulations
RU2015118162A (ru) Ветеринарный способ снижения отвращения к шуму
AR092713A1 (es) Composiciones y metodos de uso de un compuesto para el control de la inapetencia
RU2017138118A (ru) Комбинации противоглистных агентов и способы их применения
AR096854A1 (es) Composición farmacéutica para una liberación sostenida de lanreotide
EP1968585B1 (en) Veterinarian composition for use as fasciolicide in animals
ES2846820T3 (es) Composición de lactonas macrocíclicas, levamisol, un aminoazúcar y un agente antiparasitario adicional
AR055658A1 (es) Composiciones fungicidas
KR20110116231A (ko) 고 용량 도라멕틴 제형
RU2426550C1 (ru) Способ лечения телязиозов животных
AR072889A1 (es) Combinacion coccidicida para uso veterinario
AU2012303747B2 (en) Anthelmintic formulations and treatments
CL2018003269A1 (es) Ácidos carboxílicos para aplicación en la primera infancia.
CN103734132A (zh) 松材线虫杀虫剂及其在松材线虫病防治中的应用
WO2018217735A3 (en) HIGH CONCENTRATION FULVESTRANT COMPOSITIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure